Mistelikirjallisuus

       Lisätietoja tutkimuksista 

Forschungsinstitut Havelhöhe, Berlin (DE)

Institut für angewandte Erkenntnistheorie und medizinische Methodologie e. V. Freiburg i.Br. (DE)

Verein für Krebsforschung e.V., Forschungsinstitut HISCIA (CH)

Medizinische Sektion der Freien Hochschule für Geisteswissenschaft

www.mistel-therapie.de

Tutkimukset aakkosjärjestyksessä

Antony S, Kuttan R and Kuttan G. Role of natural killer cells in iscador mediated inhibition of metastasis by adoptive immunotherapy. Immunol Invest, 2000;29:219-231.

 

Antony S, Kuttan R and Kuttan G. Effect of viscum album in the inhibition of lung metastasis in mice induced by B16F10 melanoma cells. J Exp Clin Cancer Res, 1997;16:159-162

Antony S, R Kuttan and G Kuttan: Inhibition of lung metastasis by adoptive immunotherapy using Iscador. Immunol Invest. 1999; 28: 1-8.

 

Auerbach L, Dostal V, Vaclavik-Fleck I, Kubista E, Rosenberger A, Rieger S, Tröger W and Schierholz J M. Signifikant höherer Anteil aktivierter NKZellen durch additive Misteltherapie bei chemotherapierten Mamma-Ca-Patientinnen in einer prospektiv-randomisierten doppelblinden Studie [Significant Higher Level of Activated NK-Cells in Patients with Breast Cancer Receiving Viscurn alburn Extract] during Chemotherapy. In: Scheer R, Bauer H. Becker R et al. Fortschritte  in der Misteltherapie. Stand der Forschung und klinischen Anwendung. Essen, KVC Verlag, 2005. S.543-554.

 

Augustin M, Bock P R, Hanisch J, Karasmann M and Schneider B. Safety and efficacy of the long-term adjuvant treatment of primary intermediate- to high-risk malignant melanoma (UICC/AJCC stage II and III) with a standardized fermented European mistletoe (Viscum album L.) extract. Arzneimittelforschung, 2005;55:38-49. DOI: 10.1055/s-0031-1296823.

 

Axtner J, Steele M, Kroz M, Spahn G, Matthes H and Schad F. Health services research of integrative oncology in palliative care of patients with advanced pancreatic cancer. BMC Cancer, 2016;16:579. DOI: 10.1186/s12885-016-2594-5.

Bar-Sela G, Wollner M, Hammer L, Agbarya A, Dudnik E and Haim N. Mistletoe as complementary treatment in patients with advanced non-small-cell lung cancer treated with carboplatin-based combinations: a randomised phase II study. Eur J Cancer, 2013;49:1058-1064 DOI: 10.1016/j.ejca.2012.11.007.

 

Bar-Sela, G. White-Berry Mistletoe (Viscum album L.) as complementary treatment in cancer: Does it help? European Journal of Integrative Medicine 2011;3:e55-e62. DOI: 10.1016/j.eujim.2011.03.002.

 

Bauer C, Oppel T, Rueff F and Przybilla B. Anaphylaxis to viscotoxins of mistletoe (Viscum album) extracts. Ann Allergy Asthma Immunol, 2005;94:86-89. DOI:10.1016/S1081-1206(10)61291-4.

 

Becker H und JM Scher (2005). Kurzer Überblick über die Inhaltsstoffe der Mistel (Viscum album L.).  In: Scheer R,  Bauer R.  Becker H,  Fintelmann V Kemper FH Kemper und Schilcher H (Hrsg.): Fortschritte in der Misteltherapie, Aktueller Stand der Forschung und klinische Anwendung. S. 3-11.  KVC Verlag Essen 2005. ISBN 3-933351-49-9.

 

Ben-Arye E, Dahan O, Shalom-Sharabi I, Samuels N. Inverse relationship between reduced fatigue and severity of anemia in oncology patients treated with integrative medicine: understanding the paradox. Supportive Care in Cancer 2018; 10 pp. DOI: 10.1007/s00520-018-4271-5

 

Beuth J, Schneider B and Schierholz J M. Impact of complementary treatment of breast cancer patients with standardized mistletoe extract during aftercare: a controlled multicenter comparative epidemiological cohort study. Anticancer Res, 2008;28:523-527.

 

Biegel U, Stratmann N, Knauf Y, Ruess K, Reif M, Wehrend A. Postoperative adjuvante Therapie mit einem Mistelextrakt (Viscum album ssp. album) bei Hündinnen mit Mammatumoren. Complementary Medicine Research 2017;24(3):349-357. DOI: 10.1159/000485228.

 

Bock PR, Hanisch J, Matthes H and Zänker KS. Targeting inflammation in cancer-related-fatigue: a rationale for mistletoe therapy as supportive care in colorectal cancer patients. Inflamm Allergy Drug Targets, 2014;13:105-111.

 

Bock PR, Friedel WE, Hanisch J, Karasmann M and Schneider B. [Efficacy and safety of long-term complementary treatment with standardized European mistletoe extract (Viscum album L.) in addition to the conventional adjuvant oncologic therapy in patients with primary non-metastasized mammary carcinoma. Results of a multi-center, comparative, epidemiological cohort study in Germany and Switzerland]. Arzneimittelforschung, 2004;54:456-466. DOI: 10.1055/s-0031-1296999.

 

Bodungen von U, Ruess K, Reif M, Biegel U.Kombinierte Anwendung von Strahlentherapie und adjuvanter Therapie mit einem Mistelextrakt (Viscum album L.) zur Behandlung des oralen malignen Melanoms beim Hund: Eine retrospektive Studie. Complementary Medicine Research 2017;24:358-363.

 

Bonucci M, Pastore C, Ferrera V, Fiorentini C, Fabbri A. Integrated cancer treatment in the course of metastatic pancreatic cancer: Complete resolution in 2 cases. Integrative Cancer Therapies 2018:17(3):994-999. DOI: 10.1177/1534735418755479.

 

Bouzek T. Misteltherapie bei Patienten mit Hirntumoren: 3 Kasuistiken. Der Merkurstab. Zeitschrift für Anthroposophische Medizin 2012;65(3):249-256. DOI: https://doi.org/10.14271/DMS-19966-DE.

 

Braedel-Ruoff S. Immunomodulatory effects of Viscum album extracts on natural killer cells: review of clinical trials. Forsch Komplementmed, 2010;17:63-73. DOI: 10.1159/000288702.

 

Brandenburger M, Simoes-Wüst A P, Rostock M, Rist L and Saller R. Quality-of-life of cancer patients during mistletoe therapy - An exploratory study with the additional use of questionnaires (Lebensqualität von Krebspatienten während der Misteltherapie - Eine explorative Studie mit dem zusätzlichen Einsatz von Fragebögen). In: Scheer R, Alban S, Becker H, Blaschek W, Kemper FH, Kreis W, et al., editors. Die Mistel in der Tumortherapie 3, Aktueller Stand der Forschung und klinische Anwendung. Essen: KVC Verlag; 2013.

 

Burger A M, Mengs U, Kelter G, Schuler J B and Fiebig H H. No evidence of stimulation of human tumor cell proliferation by a standardized aqueous mistletoe extract in vitro. Anticancer Res 2003;23:3801-3806.

 

Burkhart J, Walchli C, Heusser P, Weissenstein U, Baumgartner S and  Andres AC. In vitro investigation into the potential of a mistletoe extract to alleviate adverse effects of cyclophosphamide. Altern Ther Health Med. 2010; 16: 40-48.

 

Büssing A, Raak C and Ostermann T. Quality of life and related dimensions in cancer patients treated with mistletoe extract (iscador): a meta-analysis. Evid Based Complement Alternat Med, 2012;2012:219402. DOI: 10.1155/2012/219402.

 

Büssing A, Girke M, Heckmann C, Schad F, Ostermann T and Kröz M. Validation of the self-regulation questionnaire as a measure of health in quality of life research. Eur J Med Res 2009;14:223-227.

 

Büssing A, M Bischof, W Hatzmann, F Bartsch, D Soto-Vera, EM Fronk, M Gmeindl and GM Stein: Prevention of surgery-induced suppression of granulocyte function by intravenous application of a fermented extract from Viscum album L. in breast cancer patients. Anticancer Res. 2005; 25: 4753-4757.

 

Büssing A, Vervecken W, Wagner M, Wagner B, Pfuller U and Schietzel M. Expression of mitochondrial Apo2.7 molecules and caspase-3 activation in human lymphocytes treated with the ribosome-inhibiting mistletoe lectins and the cell membrane permeabilizing viscotoxins. Cytometry, 1999;37:133-139.

 

Büssing A, Rosenberger A, Stumpf C  and Schietzel M. Development of lymphocyte subsets in tumor patients after subcutaneous administration of mistletoe extracts. Forsch Komplementarmed 1999;6(4):196–204.

 

Büssing A and M Schietzel: Apoptosis-inducing properties of Viscum album L. extracts from different host trees, correlate with their content of toxic mistletoe lectins. Anticancer Res. 1999; 19: 23-28.

 

Büssing A, Schaller G and Pfuller U. Generation of reactive oxygen intermediates (ROI) by the thionins from Viscum album L. Anticancer Res, 1998;18:4291-4296.

 

Büssing, A. Induction of apoptosis by the mistletoe lectins: A review on the mechanisms of cytotoxicity mediated by Viscum album L. Apoptosis (1996) 1: 25.

 

Büssing A, Suzart K, Bergmann J, Pfuller U, Schietzel M and Schweizer K. Induction of apoptosis in human lymphocytes treated with Viscum album L. is mediated by the mistletoe lectins. Cancer Lett, 1996;99:59-72. DOI: 10.1016/0304-3835(95)04038-2.

Büssing A, Regnery A and Schweizer K. Effects of Viscum album L. on cyclophosphamide-treated peripheral blood mononuclear cells in vitro: sister chromatid exchanges and activation/proliferation marker expression. Cancer Lett, 1995;94:199-205. DOI: 10.1016/0304-3835(95)03850-v.

Büssing A, Regnery A and Schweizer K. Effects of Viscum album L. on cyclophosphamide-treated peripheral blood mononuclear cells in vitro: sister chromatid exchanges and activation/proliferation marker expression. Cancer Lett, 1995;94:199-205. DOI: 10.1016/0304-3835(95)03850-v.

 

Büssing A, Azhari T, Ostendorp H, Lehnert A and Schweizer K. Viscum album L. extracts reduce sister chromatid exchanges in cultured peripheral blood mononuclear cells. Eur J Cancer, 1994;30A:1836-1841. DOI: 10.1016/0959-8049(94)00299-k.

 

Doehmer J, Eisenbraun J. Assessment of extracts from mistletoe (Viscumalbum) for herb-drug interaction by inhibition and induction of cytochromeP450 activities. Phytother Res 2012;26:11-7. DOI: 10.1002/ptr.3473

doi: 10.1097/MD.0000000000013420.

 

Dold U, Edler L, Maurer H, Muller D, Sakellariou B, Trendelenburg F, et al. Krebszusatztherapie beim fortgeschrittenen nichtkleinzelligen Bronchialkarzinom. Multizentrische kontrollierte Studie zur Prufung der

Wirksamkeit von Iscador und Polyerga. Stuttgart, New York: G. Thieme Verlag; 1991.

Drozdoff L, Klein E, Kiechle M and Daniela P. Use of biologically-based complementary medicine in breast and gynecological cancer patients during systemic therapy. BMC Complementary and Alternative Medicine 2018; 18(1):259. 2018. 

Eisenbraun J. Intravesikaler Mistelextract bei Patienten mit nicht-muskelinvasivem Harnblasenkarzinom: Eine Phase III-Wirksamkeitsstudie - Aktueller Stand. n: Scheer R, Alban S, Becker H, Beer A-M, Blaschek W, Kreis W, et al., editors. Die Mistel in der Tumortherapie 4 Aktueller Stand der Forschung und klinische Anwendung: KVC Verlag, Essen, 2016, S. 345-354.

 

Eisenbraun J. Mistelextrakt bei Patienten mit nichtmuskelinvasivem Harnblasenkarzinom - Ergebnisse einer einarmigen Phase Ib/IIa Dosiseskalationsstudie. In: Scheer R, Alban S, Becker H, Beer A-M, Blaschek W, Kreis W, et al., editors. Die Mistel in der Tumortherapie 4 Aktueller Stand der Forschung und klinische Anwendung: KVC Verlag, Essen, 2016, S. 331-334.

 

Eisenbraun J, Scheer R, Kroz M, Schad F and Huber R. Quality of life in breast cancer patients during chemotherapy and concurrent therapy with a mistletoe extract. Phytomedicine, 2011;18:151-157. DOI: 10.1016/j.phymed.2010.06.013.

 

Elluru SR, JP Duong van Huyen, S Delignat, MD Kazatchkine, A Friboulet, SV Kaveri and J Bayry: Induction of maturation and activation of human dendritic cells: a mechanism underlying the beneficial effect of Viscum album as complimentary therapy in cancer. BMC Cancer. 2008; 8: 161.

 

Elluru S, JPD Huyen van, B Wootla, S Delignat, F Prost, VS Negi and SV Kaveri: Tumor regressive effects of Viscum album preparations – Exploration of immunomodulatory mechanisms. Medicina. 2007; 67: 85-89.

 

Elluru S, JP Duong Van Huyen, S Delignat, F Prost, J Bayry, MD Kazatchkine and SV Kaveri: Molecular mechanisms underlying the immunomodulatory effects of mistletoe (Viscum album L.) extracts Iscador. Arzneimittelforschung. 2006; 56: 461-466.

 

Elsasser-Beile U, Voss M, Schuhle R and Wetterauer U. Biological effects of natural and recombinant mistletoe lectin and an aqueous mistletoe extract on human monocytes and lymphocytes in vitro. J Clin Lab Anal, 2000;14:255-259. DOI: 10.1002/1098-2825(20001212)14:6<255::aid-jcla1>3.0.co;2-j.

 

Engdal S and Nilsen O G. In vitro inhibition of CYP3A4 by herbal remedies frequently used by cancer patients. Phytother Res, 2009;23:906-912. DOI: 10.1002/ptr.2750.

 

Eom JS, Ahn HY, Mok JH, Lee G, Jo E-J, Kim M-H, Lee K, Kim KU, Park H-K, Lee MK. Pleurodesis using mistletoe extract delivered via a spray catheter during semirigid pleuroscopy for managing symptomatic malignant pleural effusion. Respiration 2018;95:177-181. DOI: 10.1159/000481869.

 

Ernst E, K Schmidt and MK Steuer-Vogt: Mistletoe for cancer? A systematic review of randomised clinical trials. Int J Cancer. 2003; 107: 262-267.

 

Felenda JE, Gruber K and Stintzing F. In-vitro-Untersuchungen zur Hemmung der Angiogenese und der Tumorzellmigration durch einen wässrigen Extrakt aus Viscum album ssp. album, Mali. June 2019. Deutsche Zeitschrift für Onkologie 2019;51(02):81-88. DOI: 10.1055/a-0827-9646.

Fellmer KE. A clinical trial of Iscador. Br Homeopath J. 1968; 57(01): 43–7.

  

Franz H, Ziska P and Kindt A: Isolation and properties of three lectins from mistletoe (Viscum album L.). Biochem J. 1981; 195: 481-484.

 

Franz M (2003). Struktur und biologische Aktivitäten der chitinbindenden Mistellektine. Dissertation, University Tübingen.

 

Freuding M, Keinki C, Kutschan S, Micke O, Buentzel J and Huebner J. Mistletoe in oncological treatment: a systematic review: part 2: quality of life and toxicity of cancer treatment. J Cancer Res Clin Oncol 2019; 145(4):927–939.

Freuding M, KeinkiC, Micke O, Buentzel J and Huebner J. Mistletoe in oncological treatment: a systemic review: part 1: survival and safety. J Cancer Res Clin Oncol 2019;145: 695–707. 

 

Friedel W E, Matthes H, Bock P R and Zanker K S. Systematic evaluation of the clinical effects of supportive mistletoe treatment within chemo- and/or radiotherapy protocols and long-term mistletoe application in nonmetastatic colorectal carcinoma: multicenter, controlled, observational cohort study. J Soc Integr Oncol 2009;7:137-145.

 

Friess H, Beger H G, Kunz J, Funk N, Schilling M and Buchler M W. Treatment of advanced pancreatic cancer with mistletoe: results of a pilot trial. Anticancer Res 1996;16:915-920.

 

Fritz P, Dippon J, Müller S, Goletz S, Trautmann C, Pappas X, Ott G, Brauch H, Schwab M, Winter S, Mürdter T, Brinkmann F, Faisst S, Rössle S, Gerteis A, Friedel G. Is mistletoe treatment beneficial in invasive breast cancer? A new approach to an unresolved problem. Anticancer Research 2018;38:1585-1593. DOI: 10.21873/anticanres.12388.

 

Gamerith G, Amann A, Schenk B, Auer T, Lentzen H, Mügge DO, Cima KM, Löffler-Ragg J, Hilbe W, Zwierzina H. Aviscumine, a recombinant ribosomal inhibitor, increases the antitumor activity of natural killer cells. Oncology Letters 2017;14(5):5563-5568. DOI: 10.3892/ol.2017.686.

  

Grah C, Kurzeja A, Matthes B, Eichberger A, Wüstfeld A, Kunc K, Weissenstein U, Thieme C, Müssig A, Schad F and Reif M. Immun-Checkpoint-Inhibition plus Viscum album L.- Extrakt beim Lungenkarzinom. Pneumologie 2019; 73(S 01) DOI: 10.1055/s-0039-1678248. Conference: 60 Kongress der Deutschen Gesellschaft für Pneumologie und Beatmungsmedizin e. V., 2019.

 

Greenlee H, MJ DuPont-Reyes, LG Balneaves, LE Carlson, MR Cohen, G Deng, JA Johnson, M Mumber, D Seely, SM Zick, LM Boyce and D Tripathy: Clinical practice guidelines on the evidence-based use of integrative therapies during and after breast cancer treatment. CA Cancer J Clin. 2017; 67: 194-232.

 

Greenlee H, LG Balneaves, LE Carlson, M Cohen, G Deng, D Hershman, M Mumber, J Perlmutter, D Seely, A Sen, SM Zick, D Tripathy and O Society for Integrative: Clinical practice guidelines on the use of integrative therapies as supportive care in patients treated for breast cancer. J Natl Cancer Inst Monogr. 2014; 2014: 346-358.

 

Grossarth-Maticek R and Ziegler R. Randomized and non-randomized prospective controlled cohort studies in matched pair design for the long-term therapy of corpus uteri cancer patients with a mistletoe preparation (Iscador). European Journal of Medical Research, 2008;13:107-120.

 

Grossarth-Maticek R and Ziegler R. Prospective controlled cohort studies on long-term therapy of cervical cancer patients with a mistletoe preparation (Iscador). Forsch Komplementmed, 2007;14:140-147. DOI: 10.1159/000102956.

Grossarth-Maticek R and Ziegler R. Prospective controlled cohort studies on long-term therapy of ovarian cancer patients with mistletoe (Viscum album L.) extracts Iscador. Arzneimittelforschung 2007;57(10):665–678. 

Grossarth-Maticek R and Ziegler R. Efficacy and safety of the long-term treatment of melanoma with a mistletoe preparation (Iscador). Schweizerische Zeitschrift für GanzheitsMedizin, 2007, 19(6):325-332.

Grossarth-Maticek R and Ziegler R. Prospective Controlled Cohort Studies on Long-Term Therapy of Breast Cancer Patients with a Mistletoe Preparation (Iscador®). Forschende Komplementärmedizin, 2006;13:285-292. DOI: 10.1159/000095378.

Grossarth-Maticek R, Ziegler R. Randomised and non-randomised prospective controlled cohort studies in matched-pair design for the long-term therapy of breast cancer patients with a mistletoe preparation (Iscador): a reanalysis.

Eur J Med Res. 2006 Nov; 11(11): 485–95.

Grossarth-Maticek R, Kiene H, Baumgartner S, Ziegler R. Synergieeffekte von Selbstregulation und Misteltherapie (Iscador) auf die Uberlebenszeit bei Krebspatienten. Schweiz Zschr Ganzheitsmedizin. 2004; 16(2): 81–9.

Grossarth-Maticek R, Kiene H, Baumgartner S M and Ziegler R. Use of Iscador, an extract of European mistletoe (Viscum album), in cancer treatment: prospective nonrandomized and randomized matched-pair studies nested within a cohort study. Altern Ther Health Med 2001;7:57-66, 68-72, 74-56 passim.

 

Gutsch J, Werthmann P G, Rosenwald A and Kienle G S. Complete Remission and Long-term Survival of a Patient with a Diffuse Large B-cell Lymphoma Under Viscum album Extracts After Resistance to R-CHOP: A Case Report. Anticancer Res, 2018;38:5363-5369. DOI: 10.21873/anticanres.12865.

Gutsch J, S Rieger and D Schlodder (2013). Observational study on treatment of lymphocytic non-Hodkin lymphoma (CLL) with in-process-standardized Viscum album products Helixor P or A - Clinical course and safety. In: In: Scheer R, Alban S, Becker H, Blaschek W, Kemper FH, Kreis W, et al., editors.Die Mistel in der Tumortherapie 3, Aktueller Stand der Forschung und klinische Anwendung. Essen: KVC Verlag; 2013.

 

Gutsch J, S Rieger, JM Schierholz and D Schlodder (2008). Observational study on treatment with standardized Viscum album extracts (VA-E) in lymphocytic non-Hodgkin's lymphoma (CLL) - safety and course. In:  Scheer R, Alban S, Becker H et al.  Die Mistel in der Tumortherapie 2. Essen, KVC Verlag, 2009.

 

Gutsch J. Außergewöhnlicher Krankheitsverlauf bei metastasierendem Mammakarzinom unter Misteltherapie nach pseudoallergischer Reaktion. In: Scheer R, Bauer R, H B, Berg PA, Fintelmann V, editors. Die Mistel in der Tumortherapie Grundlagenforschung und Klinik. Essen: KVC Verlag; 2001. S. 379-387.

Günzler M, Salzer G. Iscadortherapie in derNachbehandlung operierter Carcinome. Österr Ärzteztg. 1969; 24(20): 2290–4.

Günzler M, Osika C, Salzer G. Ergebnisse von Resektion und Nachbehandlung beim Magenkarzinom. Wien Klin Wochenschr. 1968 Feb; 80(6): 105–6.

Hajtó T, Fodor K, Perjesi P and Nemeth P. Difficulties and perspectives of immunomodulatory therapy with mistletoe lectins and standardized mistletoe extracts in evidence-based medicine. Evid Based Complement Alternat Med, 2011;2011:298972. DOI: 10.1093/ecam/nep191.

 

Hajtó T, Hostanska K, Frei K, Rordorf C and Gabius HJ. Increased secretion of tumor necrosis factor α, interleukin 1, and interleukin 6 by human mononuclear cells exposed to β-galactoside-specific lectin from clinically applied mistletoe extract. Cancer Research 1990;50(11):3322-3326. 

 

Hajtó T. Immunomodulatory effects of iscador: a Viscum album preparation. Oncology 1986; 43(1):51–65. DOI:10.1159/000226420.

 

Hoffmann J, Hajtó T. Iscadorbehandlung beim metastasierenden Mammakarzinom. Krebsgeschehen. 1982;(3): 71–5.

Hall A H, Spoerke D G and Rumack B H. Assessing mistletoe toxicity. Ann Emerg Med 1986;15:1320-1323.

Hamre HJ, Witt CM, Kienle GS, Glockmann A, Stefan NW and Helmut K. Predictors of outcome after 6 and 12 months following anthroposophic therapy for adult outpatients with chronic disease: a secondary analysis from a prospective observational study. BMC Research Notes 2010;3:218. 

Heinzerling L, von Baehr V, Liebenthal C, von Baehr R and Volk H D. Immunologic effector mechanisms of a standardized mistletoe extract on the function of human monocytes and lymphocytes in vitro, ex vivo, and in vivo. J Clin Immunol, 2006;26:347-359. DOI: 10.1007/s10875-006-9023-5.

 

Hoffmann J. Die Iscador-Behandlung bei Lebermetastasen. Krebsgeschehen. 1979;(6):172–5.

Horneber MA, Bueschel G, Huber R, Linde K and Rostock M. Mistletoe therapy in oncology. Cochrane Database Syst Rev, 2008:CD003297. DOI: 10.1002/14651858.CD003297.pub2.

 

Huber R and Gründemann C. Die Wirkungen der Mistelsubstanz auf das Immunsystem und mögliche therapeutische Implikationen. Der Merkurstab, Zeitschrift für Antroposophische Medizin, 2018;71:265-268.

 

Huber R, Schlodder D, Effertz C, Rieger S and Tröger W. Safety of intravenously applied mistletoe extract – results from a phase I dose escalation study in patients with advanced cancer. BMC Complementary and Alternative Medicine (2017) 17:465. DOI 10.1186/s12906-017-1971-1

 

Huber R, Lüdtke H, Wieber J and Beckmann C. Safety and effects of two mistletoe preparations on production of Interleukin-6 and other immune parameters - a placebo controlled clinical trial in healthy subjects. BMC Complementary and Alternative Medicine, vol. 11, no. 116, 2011. DOI: doi.org/10.1186/1472-6882-11-116.

 

Huber R, Classen K, Werner M and Klein R. In vitro immunoreactivity towards lectin-rich or viscotoxin-rich mistletoe (Viscum album L.) extracts Iscador applied to healthy individuals. Arzneimittelforschung, 2006;56:447-456. DOI: 10.1055/s-0031-1296811.

 

Huber R, Rostock M, Goedl R, Ludtke R, Urech K, Buck S and Klein R. Mistletoe treatment induces GM-CSF- and IL-5 production by PBMC and increases blood granulocyte- and eosinophil counts: a placebo controlled randomized study in healthy subjects. Eur J Med Res, 2005;10:411-418.

 

Huebner J, Freuding M, Keinki C, Micke O, and Buentzel J. Answer to the letter to the editors by Matthes and colleagues regarding our systematic reviews on mistletoe. J Cancer Res Clin Oncol 2019;145(9):2409-2410.

Hutt N, Kopferschmitt-Kubler M, Cabalion J, Purohit A, Alt M and Pauli G. Anaphylactic reactions after therapeutic injection of mistletoe (Viscum album L.). Allergologia et immunopathologia, 2001;29:201-203.

 

Janssen O, Scheffler A and Kabelitz D. In vitro effects of mistletoe extracts and mistletoe lectins. Cytotoxicity towards tumor cells due to the induction of programmed cell death (apoptosis). Arzneimittelforschung, 1993;43:1221-1227.

 

Kelter G and HH Fiebig: Absence of tumor growth stimulation in a panel of 26 human tumor cell lines by mistletoe (Viscum album L.) extracts Iscador in vitro. Arzneimittelforschung. 2006; 56: 435-440.

 

Kempenich R, Willeke M, Meyer U. Das Prostatakarzinom und seine Behandlung mit Iscucin® Populi - Einführung und klinische Fälle aus der Praxis. Der Merkurstab. Zeitschrift für Anthroposophische Medizin 2009;62(3):255-261. DOI: https://doi.org/10.14271/DMS-19439-DE .

 

Kienle G S, Mussler M, Fuchs D and Kiene H. The Subjective Dimension of Integrative Cancer Care: A Qualitative Study Exploring the Perspectives, Themes, and Observations of Experienced Doctors from the Area of Anthroposophic Medicine. Explore (NY), 2018;14:342-351. DOI: 10.1016/j.explore.2018.03.007.

 

Kienle G S, Mussler M, Fuchs D and Kiene H. Intravenous Mistletoe Treatment in Integrative Cancer Care: A Qualitative Study Exploring the Procedures, Concepts, and Observations of Expert Doctors. Evid Based Complement Alternat Med, 2016;2016:4628287. DOI: 10.1155/2016/4628287.

 

Kienle GS, Grugel R and Kiene H. Safety of higher dosages of Viscum album L. in animals and humans - systematic review of immune changes and safety parameters. BMC Complementary and Alternative Medicine 2011, 11:72. 

 

Kienle GS and Kiene H. Review article: Influence of Viscum album L (European mistletoe) extracts on quality of life in cancer patients: a systematic review of controlled clinical studies. Integr Cancer Ther, 2010;9:142-157. DOI: 10.1177/1534735410369673.

Kienle, G.S., A. Glockmann, M. Schink, and H. Kiene Viscum album L. extracts in breast and gynaecological cancers: a systematic review of clinical and preclinical research. J Exp Clin Cancer Res 2009;28:79. DOI: 1756-9966-28-79 [pii]10.1186/1756-9966-28-79.

 

Kienle GS, Kiene H. Cancer therapy: a systematic review of prospective clinical trials on anthroposophic mistletoe extracts. Eur J Med Res 2007; 12:103-119.

 

Kienle GS, Kiene H, Albonico HU: Anthroposophic Medicine: Effectiveness, Utility, Costs, Safety. Stuttgart, New York: Schattauer Verlag; 2006.

Kienle GS, Kiene H. Kontrollierte klinische Studien zur Misteltherapie der Krebserkrankung – eine systematische Übersicht. In: Fortschritte in der Misteltherapie. Aktueller Stand der Forschung und klinische Anwendung. In: Scheer R, Bauer R, Becker H, Fintelmann V, Kemper F, Schilcher H. (Hrsg.) KVC Verlag, Essen 2005;405-421.

Kienle GS, F Berrino, A Büssing, E Portalupi, S Rosenzweig and H Kiene: Mistletoe in cancer - a systematic review on controlled clinical trials. Eur J Med Res. 2003; 8: 109-119.

 

Kienle GS and H Kiene H. Verträglichkeit, Nebenwirkungen, Überempfindlichkeitsreaktionen, Toxizität. Die Mistel in der Onkologie. Fakten und konzeptionelle Grundlagen. Stuttgart, New York, Schattauer Verlag, 2003. S.591-60.

 

Kim S, Kim K-C, Lee C. Mistletoe (Viscum album) extract targets Axl to suppress cell proliferation and overcome cisplatin- and erlotinib-resistance in non-small cell lung cancer cells. Phytomedicine 2017;36:183-193. DOI: 10.1016/j.phymed.2017.09.017.

 

Kim K-C, Yook J-H, Eisenbraun J, Kim B-S and Huber R. Quality of life, immunomodulation and safety of adjuvant mistletoe treatment in patients with gastric carcinoma–a randomized, controlled pilot study. BMC Complementary and Alternative Medicine, 2012;12:172.

 

Kleeberg U R, Suciu S, Brocker E B, Ruiter D J, Chartier C, Lienard D, Marsden J, Schadendorf D, Eggermont A M and Society E M G i c w t G C. Final results of the EORTC 18871/DKG 80-1 randomised phase III trial. Eur J Cancer, 2004;40:390-402.

 

Kleijnen J, Knipschild P. Mistletoe treatment for cancer - review of controlled trials in humans. Phytomedicine, 1994;1:255-260.

Klein R, Franz M, Wacker R, Classen K, Scheer R, von Laue HB, Stoeva S and Voelter W. Demonstration of antibodies to the chitin-binding mistletoe lectin (cbML) in tumor patients before and during therapy with an aqueous mistletoe extract. Eur J Med Res 2004;9:316-322.

Klein R, Classen K, Berg PA, Lüdtke R, Werner M  and Huber R. In vivo-induction of antibodies to mistletoe lectin-1 and viscotoxin by exposure to aqueous mistletoe extracts: a randomised double-blinded placebo controlled phase I study in healthy individuals. European Journal of Medical Research, 2002;7(4):155–163, 2002.

 

Klett CY and Anderer FA. Activation of natural killer cell cytotoxicity of human blood monocytes by a low molecular weight component from viscum album extract. Arzneimittelforschung 1989;39:1580-1585.

 

Kovacs E, Link S and Toffol-Schmidt U. Cytostatic and cytocidal effects of mistletoe (Viscum album L.) quercus extract Iscador. Arzneimittelforschung, 2006;56:467-473. DOI: 10.1055/s-0031-1296814.

 

Kovacs E, Hajto T and Hostanska K. Improvement of DNA repair in lymphocytes of breast cancer patients treated with Viscum album extract (Iscador). Eur J Cancer, 1991;27:1672-1676.

 

Kröz M, Mehl A, Didwiszus A, Gelin-Kröz B, Reif M, Berger B, ten Brink F, Zerm R, Girke M, Gutenbrunner C and Büssing A. Reliability and first validity of the inner correspondence questionnaire for painting therapy (ICPTh) in a sample of breast cancer patients. Complementary Therapies in Medicine. 2019;42:355-360.

 

Kröz M, Büssing A, Reif M, Pranga D, Schad F, Zerm R, Matthes H and Girke M. (2016).Besteht eine Indikation für die Misteltherapie in der Behandlung von Cancer-related Fatigue und Insomnie bei Krebspatienten? –  Ein Review. In: Scheer R, Alban S, Becker H, Beer A-M, Blaschek W, Kreis W, et al., editors. Die Mistel in der Tumortherapie 4. Aktueller Stand der Forschung und klinische Anwendung: KVC Verlag, Essen, 2016, S.287-298.

 

Kröz M, Büssing A, von Laue B H, Reif M, Feder G, Schad F, Girke M and Matthes H. Reliability and validity of a new scale on internal coherence (ICS) of cancer patients. Health Qual Life Outcomes, 2009;7:59. DOI:10.1186/1477-7525-7-59.

 

Kröz M, Zerm R, Reif M, von Laue B H, Schad F, Bussing A, Bartsch C, Feder G and Girke M. Validation of the German version of the Cancer Fatigue Scale (CFS-D). Eur J Cancer Care (Engl), 2008;17:33-41. DOI: 10.1111/j.1365-2354.2007.00799.x

 

Kuehn JJ (2009). Viscum album L. Pini in der Behandlung des Non-Hodgkin-Lymphoms - Wirksamkeit und Risikoeinschätzung einer subkutanen Misteltherapie im Rahmen einer retrospektiven Fallkontrollstudie. In:  Scheer R, Alban S, Becker H et al.  Die Mistel in der Tumortherapie 2. Essen, KVC Verlag, 2009: S.353-373.

 

Kuehn JJ. Treatment responses to Viscum album pini (Iscador P) in non-Hodgkin's lymphoma exploring a new therapeutic route. Medicina 2007;67:107-114.

 

Kunz C, Heiligtag HR, Hintze A and K Urech K (2013). Topische Behandlung des Basalzellkarzinoms mit Viscum album, lipophiler Extrakt 10%, Unguentum - Eine Fallserie-Studie, S.315-322. In: Scheer R, Alban S, Becker H, Blaschek W, Kemper FH, Kreis W, et al., editors. Die Mistel in der Tumortherapie 3, Aktueller Stand der Forschung und klinische Anwendung. Essen: KVC Verlag; 2013.

 

Kuttan G and Kuttan R: Reduction of leukopenia in mice by "viscum album" administration during radiation and chemotherapy. Tumori 1993;79:74-76.

 

Kuttan G, Vasudevan DM and R Kuttan R. Isolation and identification of a tumour reducing component from mistletoe extract (Iscador). Cancer Lett 1988;41:307-314.

 

Kuttan R and Kuttan G. Inhibition of lung metastasis by adoptive immunotherapy using Iscador. Immunol Invest, 1999;28:1-8.

 

Lange-Lindberg A M, Velasco Garrido M and Busse R. Mistletoe treatments for minimising side effects of anticancer chemotherapy. GMS Health Technol Assess 2006;2:Doc18.

 

Leroi R, Hajto T. Die Iscadortherapie beim Ovarialkarzinom. Krebsgeschehen. 1982;14(2): 38–44.

Leroi R. Die Iscadorbehandlung bei inoperablen kolo-rektalen Tumoren. Krebsgeschehen. 1979; 11(6): 163–5.

Leroi R. Nachbehandlung des operierten Mammakarzinoms mit Viscum album. Helv Chir Acta. 1977 Jun; 44(3): 403–14.

Leroi R. Malignomtherapie mit neuen Iscador-Praparaten. Krebsgeschehen. 1975; 7(5):124–6.

Lipp HP. Mythos Mistel – Metaanalysen, neuere Studiendaten und aktuelle Marktübersicht. Krankenhauspharmazie 2017;12:543-555.

Loef, Walach H.  Quality of Life in Cancer Patients Treated  with Mistletoe: a Systematic Review and Meta-analysis. Pre-print published at medRxivorg 2020. DOI: http://dx.doi.org/10.1101/19013177.

 

Loewe-Mesch A, Kuehn J J, Borho K, Abel U, Bauer C, Gerhard I, Schneeweiss A, Sohn C, Strowitzki T and v Hagens C. [Adjuvant simultaneous mistletoe chemotherapy in breast cancer--influence on immunological parameters, quality of life and tolerability]. Forsch Komplementmed, 2008;15:22-30. DOI: 10.1159/000112860.

 

Longhi A, Reif M, Mariani E and Ferrari S. A Randomized Study on Postrelapse Disease-Free Survival with Adjuvant Mistletoe versus Oral Etoposide in Osteosarcoma Patients. Evid Based Complement Alternat Med, 2014;2014:210198. DOI: 10.1155/2014/210198.

 

Longhi A, Mariani E and Kuehn J J. A randomized study with adjuvant mistletoe versus oral Etoposide on post relapse disease-free survival in osteosarcoma patients. Eur J Integr Med, 2009;1:31-39.

 

Lyman GH, Greenlee H, Bohlke K, Bao T, DeMichele AM, Deng GE,  Fouladbakhsh JM, Gil B, Hershman DL, Mansfield S, Mussallem DM, Mustian KM, Price E, Rafte S and Lorenzo Cohen. Integrative Therapies During and After Breast Cancer Treatment: ASCO Endorsement of the SIO Clinical Practice Guideline. J Clin Oncol.2018:36:2647-2655.

 

Mabed M, El-Helw L and Shamaa S. Phase II study of viscum fraxini-2 in patients with advanced hepatocellular carcinoma. British Journal of Cancer, 2004;90:65-69. DOI: 10.1038/sj.bjc.6601463.

 

Maier G, Fiebig HH. Absence of tumor growth stimulation in a panel of 16 human tumor cell lines by mistletoe extracts in vitro. Anticancer Drugs. 2002 Apr;13(4):373-9.

 

Maldacker J. Preclinical investigations with mistletoe (Viscum album L.) extract Iscador. Arzneimittelforschung, 2006;56:497-507. DOI: 10.1055/s-0031-1296817.

 

Mansky PJ, Wallerstedt DB, Sannes TS, Stagl J, Johnson LL, Blackman MR, Grem JL, Swain SM and Monahan BP. NCCAM/NCI Phase 1 Study of Mistletoe Extract and Gemcitabine in Patients with Advanced Solid Tumors. Evid Based Complement Alternat Med. 2013;2013:964592. doi:10.1155/2013/964592. Epub 2013 Oct 27.

 

Matthes H, Thronicke A, Hofheinz R-D, Baars E, Martin D, Huber R,  Breitkreuz T, Bar-Sela G,  Galun D and Schad F. Statement to an Insufficient Systematic Review on Viscum album L. Therapy.  Evidence-Based Complementary and Alternative Medicine, Volume 2020, Article ID 7091039, 9 pages. Open Access. 

 

Matthes H, Hofheinz RD, Bar-Sela D, Galun D, Martin D, Huber R, Langhorts J, Matthiessen PF and Schad F. Letter to the editors of the Journal of Cancer Research and Clinical Oncology. J Cancer Res Clin Oncol 2019;145: 2405–2407

 

Matthes H. Die Misteltherapie in der Onkologie – ein Update. Praxismagazin 2017;9:6-14.

 

Matthes H, Friedel W E, Bock P R and Zanker K S. Molecular mistletoe therapy: friend or foe in established anti-tumor protocols? A multicenter, controlled, retrospective pharmaco-epidemiological study in pancreas cancer. Curr Mol Med, 2010;10:430-439. DOI: 10.2174/156652410791317057.

 

Melzer J, Iten F, Hostanska K and Saller R. Efficacy and safety of mistletoe preparations (Viscum album) for patients with cancer diseases. A systematic review. Forsch Komplementmed, 2009;16:217-226. DOI: 10.1159/000226249.

 

Matthiessen PF, Tröger W. Die Misteltherapie des Krebses. In Kombinierte Tumortherapie. (Ed. Wrba H) pp. 271-290, Hippokrates Verlag, Stuttgart 1995.

Micke O, Buntzel J, Kisters K, Schäfer U, Micke P and Mücke R. Complementary and alternative medicine in lung cancer patients: a neglected phenomenon? Frontiers of Radiation Therapy and Oncology 2009;42:198–205. 

Mueller EA and Anderer FA. A Viscum album oligosaccharide activating human natural cytotoxicity is an interferon gamma inducer. Cancer Immunol Immunother 1990;32:221-227.

 

Mulsow K, Enzlein T, Delebinski C, Jaeger S, Seifert G and Melzig MF. Impact of Mistletoe Triterpene Acids on the Uptake of Mistletoe Lectin by Cultured Tumor Cells. PLOS One 2016;11: e0153825.

 

Nazaruk J and Orlikowski P. Phytochemical profile and therapeutic potential of Viscum album L. Nat Prod Res 2016;30:373-385.

 

Oei S L, Thronicke A and Schad F. Mistletoe and Immunomodulation: Insights and Implications for Anticancer Therapies. Evid Based Complement Alternat Med, 2019;2019:5893017. DOI: 10.1155/2019/5893017.

 

Oei SL, Thronicke A, Kröz M, Herbstreit C and Schad F. Supportive effect of Viscum album L. extracts on the sense of coherence in non-metastasized breast cancer patients. European Journal of Integrative Medicine. 2019;27:97-104.

 

Oei SL, Thronicke A, Kröz M, Matthes H and Schad F. Use and Safety of Viscum album L Applications in Cancer Patients With Preexisting Autoimmune Diseases: Findings From the Network Oncology Study. Integr Cancer Ther. 2019;18:1534735419832367.

 

Oei SL, Thronicke A, Kröz M, Herbstreit C and Schad F. The Internal Coherence of Breast Cancer Patients Is Associated with the Decision-Making for Chemotherapy and Viscum album L. Treatment. Evid Based Complement Alternat Med 2018;2018:1065271.

 

Orange M, Lace A, Fonseca M P, von Laue B H, Geider S and Kienle GS. Durable Regression of Primary Cutaneous B-Cell Lymphoma Following Fever-inducing Mistletoe Treatment: Two Case Reports. Glob Adv Health Med, 2012;1:18-25. DOI: 10.7453/gahmj.2012.1.1.006.

 

Orange M, Fonseca MP, Lace A, von Laue  HB and Geider S. Durable tumour responses following primary high does induction with mistletoe extracts. Two case reports. European Journal of Integrative Medicine, 2010;2:63-69. DOI: 10.1016/j.eujim.2010.04.001.

  

Ostermann T, Appelbaum S, Poier D, Boehm K, Raak C and Büssing A. A Systematic Review and Meta-Analysis on the Survival of Cancer Patients Treated with a Fermented Viscum album L. Extract (Iscador): An Update of Findings. Complement Med Res. 2020 Jan 10:1-12. doi: 10.1159/000505202. [Epub ahead of print]

 

Ostermann T and Büssing A. Retrolective studies on the survival of cancer patients treated with mistletoe extracts: a meta-analysis. Explore (NY) 2012;8:277-281. 

Ostermann T, Raak C and Bussing A. Survival of cancer patients treated with mistletoe extract (Iscador): a systematic literature review. BMC Cancer, 2009;9:451. DOI: 10.1186/1471-2407-9-451.

Pae HO, Oh GS, Seo WG, Shin MK, Hong SG, Lee HS and Chung HT. Mistletoe lectin synergizes with paclitaxel in human SK-hep1 hepatocarcinoma cells. Immunopharmacol Immunotoxicol 2001;23: 531-540.

 

Paepke D. Die Misteltherapie in der Onkologie. Im Focus Onkologie 2018;21:64–68. 

Pal A, Debreczeni JE, Sevvana M, Gruene T, Kahle B, Zeeck A and Sheldrick GM. Structures of viscotoxins A1 and B2 from European mistletoe solved using native data alone. Acta Crystallogr D Biol Crystallogr 2008;64:985-992.

 

Pal A. Structure determination of Viscotoxin A1, Tendamistat and Tri Peptidyl Peptidase-I. Dissertation. Göttingen 2008, University Göttingen.

 

Pelzer F, Tröger W and Nat D R. Complementary Treatment with Mistletoe Extracts During Chemotherapy: Safety, Neutropenia, Fever, and Quality of Life Assessed in a Randomized Study. J Altern Complement Med, 2018;24:954-961. DOI: 10.1089/acm.2018.0159.

 

Pfüller U (2000). Chemical constituents of European mistletoe (Viscum album L.). In: Büssing A: Mistletoe - The Genus Viscum. pp 1-122.  Amsterdam, Harwood Academic Publishers Amsterdam 2000.

 

Piao B K, Wang Y X, Xie G R, Mannsmann U, Matthes H, Beuth J and Lin H S. Impact of complementary mistletoe extract treatment on quality of life in breast, ovarian and non-small cell lung cancer patients. A prospective randomized controlled clinical trial. Anticancer Research 2004;24:303-310.

 

Pichler W J and Angeli R. [An allergy to mistletoe extract]. Dtsch Med Wochenschr, 1991;116:1333-1334.

 

Pietrzak W, Nowak R, Gawlik-Dziki U, Lemieszek MK, Rzeski W. LC-ESI-MS/MS identification of biologically active phenolic compounds in mistletoe berry extracts from different host trees. Molecules 2017;22:264. DOI: 10.3390/molecules22040624.

 

Podlech OP, Harter PN, Mittelbronn M, Pöschel S and Naumann U. Fermented mistletoe extract as a multimodal antitumoral agent in gliomas. Evid Based Complement Alternat Med. 2012;2012:501796. doi: 10.1155/2012/501796. Epub 2012 Oct 22. 

 

Poier D, Bussing A, Rodrigues Recchia D, Beerenbrock Y, Reif M, Nikolaou A, Zerm R, Gutenbrunner C and Kröz M. Influence of a Multimodal and Multimodal-Aerobic Therapy Concept on Health-Related Quality of Life in Breast Cancer Survivors. Integr Cancer Ther. 2019;18:1534735418820447.

 

Reynel M, Villegas Y, Werthmann PG, Kiene and Kienle GS. Long-term survival of a patient with an inoperable thymic neuroendocrine tumor stage IIIa under sole treatment with Viscum album extract

A CARE compliant clinical case report. Medicine (Baltimore). 2020 Jan; 99(5): e18990. Published online 2020 Jan 31. doi: 10.1097/MD.0000000000018990

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7004773/

 

Reynel M, Villegas Y, Kiene H, Werthmann PG, Kienle GS . Bilateral Asynchronous Renal Cell Carcinoma With Lung Metastases: A Case Report of a Patient Treated Solely With High-dose Intravenous and Subcutaneous Viscum album Extract for a Second Renal Lesion. Anticancer Res. 2019 Oct;39(10):5597-5604. doi: 10.21873/anticanres.13754.

 

Reynel M,  Villegas Y,  Kiene H, Werthmann P and Kienle GS.  Intralesional and subcutaneous application of Viscum album L.(European mistletoe) extract in cervical carcinoma in situ: A CARE compliant case report. Medicine: November 2018 - Volume 97 - Issue 48 - p e13420 doi: 10.1097/MD.0000000000013420. 

 

Ribereau-Gayon G, Jung ML, Baudino S, Salle G and Beck JP. Effects of mistletoe (Viscum album L.) extracts on cultured tumor cells. Experientia 1986;42:594-599.

 

Rieger S. Immunologische Effekte verschiedener Mistelextrakte in Wechselwirkung mit humanen Tumorzellüberständen – ein Modell mit Dendritischen Zellen. Dissertation, Universität Freiburg, 2015.

 

Saha C, Das M, Stephen-Victor E, Friboulet A, Bayry J and Kaveri S V. Differential Effects of Viscum album Preparations on the Maturation and Activation of Human Dendritic Cells and CD4(+) T Cell Responses. Molecules, 2016;21. DOI: 10.3390/molecules21070912.

 

Salzer G, Danmayr E, Wutzlhofer F, Frey S. Adjuvante Iscador-Behandlung operierter  nicht kleinzelliger Bronchuskarzinome. Ergebnisse einer randomisierten Studie. Dtsch Z Onkol. 1991; 23(4): 94–8.

Salzer G, Havelec L. Adjuvante Iscador-Behandlung nach operiertem Magenkarzinom.  Ergebnisse einer randomisierten Studie.

Krebsgeschehen. 1983; 15(4): 106–10.

Salzer G, Havelec L. Rezidivprophylaxe bei operierten Bronchuskarzinompatienten mit dem Mistelpraparat Iscador: Ergebnisse

eines klinischen Versuchs aus den Jahren 1969-1971. Onkologie. 1978 Dec; 1(6): 264–7.

Sander F. Wirkung des Mistellektin-l auf das Wachstums- und Metastasierungsverhalten der humanen Melanomzelllinie MV3 in vivo in einem Xenograftmodell mit scid- und pfp/rag2-Mäusen. Dissertation, University Hamburg, 2008.

 

Schad F, Thronicke A, Steele M L, Merkle A, Matthes B, Grah C and Matthes H. Overall survival of stage IV non-small cell lung cancer patients treated with Viscum album L. in addition to chemotherapy, a real-world observational multicenter analysis. PLoS One, 2018;13:e0203058. DOI: 10.1371/journal.pone.0203058.

 

Schad F, Thronicke A, Merkle A, Steele M, Kröz M, Herbstreit C and Matthes H. Implementation of an integrative oncological concept in daily care of a German certified Breast Cancer Centre. Complement Med Res 2018;25:85-91.

 

Schad F, Axtner J, Kroz M, Matthes H and Steele M L. Safety of Combined Treatment With Monoclonal Antibodies and Viscum album L Preparations. Integr Cancer Ther, 2018;17:41-51. DOI: 10.1177/1534735416681641.

 

Schad F, Thronicke A, Merkle A, Matthes H and Steele ML. Immune-related and adverse drug reactions to low versus high initial doses of Viscum album L. in cancer patients. Phytomedicine 2017;36:54-58.

 

Schad F, Axtner J, Happe A, Breitkreuz T, Paxino C, Gutsch J, Matthes B, Debus M, Kröz M, Spahn G, Riess H, von Laue HB and Matthes H. Network Oncology (NO)--a clinical cancer register for health services research and the evaluation of integrative therapeutic interventions in anthroposophic medicine. Forsch Komplementmed 2013;20:353-360.

 

Scheer R., Alban S., Becker H., Beer A.-M., Blaschek W., Kreis. W., Matthes H., Schilcher H.† , Spahn G., Stange R. (Hrsg.): "Die Mistel in der Tumortherapie - 4, aktueller Stand der Forschung und klinische Anwendung", 469 Seiten, KVC-Verlag Essen 2016, ISBN 978-3-945150-68-9. Sisällysluettelo
 

Scheer R., Alban S., Becker H., Blaschek W., Kemper F.H., Kreis. W., Matthes H., Schilcher H., Stange R. (Hrsg.): "Die Mistel in der Tumortherapie - 3, aktueller Stand der Forschung und klinische Anwendung", 502 Seiten, KVC-Verlag Essen 2013, ISBN 978-3-86864-032-8.
 

Scheer R., Alban S., Becker H., Holzgrabe U., Kemper F.H., Kreis W., Matthes H., Schilcher H. (Hrsg.): "Die Mistel in der Tumortherapie 2, Aktueller Stand der Forschung und klinische Anwendung", 642 Seiten, KVC-Verlag Essen 2009, ISBN 978-3-933351-82-1.
 

Scheer R., Bauer R., Becker H., Fintelmann V., Kemper F.H., Schilcher H. (Hrsg.): "Fortschritte in der Misteltherapie, Aktueller Stand der Forschung und klinische Anwendung", 662 Seiten, KVC Verlag Essen 2005, ISBN 3-933351-49-9. 

 

Schink M and Dehus O. Effects of mistletoe products on pharmacokinetic drug turnover by inhibition and induction of cytochrome P450 activities. BMC Complement Altern Med, 2017;17:521. DOI: 10.1186/s12906-017-2028-1.

 

Schink M, Tröger W, Goyert A, Scheuerecker H, Meyer J, Fischer I and Glaser F (2009). Einfluss perioperativer Mistelextrakt-Infusionen auf eine operations- und narkosebedingte Immunsuppression bei Patienten mit kolorektalem Karzinom. S. 441-454. Die Mistel in der Tumortherapie 2. R. Scheer, S. Alban, H. Becker et al. Essen, KVC Verlag. 2009: S. 441-454.

 

Schink M, Tröger W, Dabidian A, Goyert A, Scheuerecker H, Meyer J, Fischer I U and Glaser F. Mistletoe extract reduces the surgical suppression of natural killer cell activity in cancer patients. a randomized phase III trial. Forsch Komplementmed, 2007;14:9-17. DOI: 10.1159/000098135.

 

Schink M, Tröger W, Goyert A, Scheuerecker H, Selbmann H K and Glaser F. [Correlation of NK cell activity against autologous tumour cells and K562 cells with the clinical outcome during therapy with mistletoe extracts]. Forsch Komplementmed, 2006;13:147-155. DOI: 10.1159/000092624.

 

Schink M and M Borowsky (2001). Zytotoxische Effekte von Mistellektinen und einem Mistelpräparat auf menschliche natürliche Killerzellen in vitro.  163-176. In: Scheer R., Bauer R., Becker H., Berg P. A., Fintelmann V. (Hrsg.): Die Mistel in der Tumortherapie, Grundlagenforschung und Klinik: 163-176. KVC Verlag Essen 2001, ISBN 3-933351-22-7

 

Schläppi M, Ewald C, Kuehn JJ, Weinert T and Huber R. Fever Therapy With Intravenously Applied Mistletoe Extracts for Cancer Patients: A Retrospective Study. Integrative Cancer Therapies 2016;16(4):479-484.

 

Schötterl S, Huber SM, Lentzen H, Mittelbronn M, Naumann U.Adjuvant therapy using mistletoe containing drugs boosts the T-cell-mediated killing of glioma cells and prolongs the survival of glioma bearing mice. Evidence-Based Complementary and Alternative Medicine 2018. Article ID 3928572. 12 pp. DOI: 10.1155/2018/3928572.

 

Schuppli R. Die adjuvante Behandlung des malignen Melanoms mit Iscador c. Hg. In: Jungi WF, Senn HJ, editors. Krebs und Alternativmedizin II. Berlin, Heidelberg: Springer Verlag; 1990. p. 84–87.

Siegle I, Fritz P, McClellan M, Gutzeit S and Murdter TE. Combined cytotoxic action of Viscum album agglutinin-1 and anticancer agents against human A549 lung cancer cells. Anticancer Res 2001;21:2687-2691.

 

Stammer RM, Kleinsimon S, Rolff J, Jäger S, Eggert A, Seifert G, Delebinski CI (2017) Synergistic antitumour properties of viscumTT in alveolar rhabdomyosarcoma. Journal of Immunology Research 2017. 13 pp. Article ID 4874280. DOI: 10.1155/2017/4874280.

Stauder H, Kreuser ED. Mistletoe extracts standardised in terms of mistletoe lectins (ML I) in oncology: current state of clinical research. Onkologie. 2002;25:374-380.

Steele ML, Axtner J, Happe A, Kröz M, Matthes H and Schad F. Use and Safety of Intratumoral Application of European Mistletoe (Viscum album L) Preparations in Oncology. Integrative Cancer Therapies, 2015;14:140-148. DOI: 10.1177/1534735414563977.

 

Steele ML, Axtner J, Happe A, Kroz M, Matthes H and Schad F. Adverse Drug Reactions and Expected Effects to Therapy with Subcutaneous Mistletoe Extracts (Viscum album L.) in Cancer Patients. Evid Based Complement Alternat Med, 2014;2014:724258. DOI: 10.1155/2014/724258.

 

Steele ML, Axtner J, Happe A, Kroz M, Matthes H and Schad F. Safety of Intravenous Application of Mistletoe (Viscum album L.) Preparations in Oncology: An Observational Study. Evid Based Complement Alternat Med, 2014;2014:236310. DOI:10.1155/2014/236310.

 

Stein GM, U Edlund, G Schaller, U Pflüller, A Büssing and M Schietzel (2001). Polysaccharide und Viscotoxine – Immunologische Wirkungen und Interaktionen. In: Scheer R., Bauer R., Becker H., Berg P. A., Fintelmann V. (Hrsg.): Die Mistel in der Tumortherapie, Grundlagenforschung und Klinik:.145-161. KVC Verlag Essen 2001, ISBN 3-933351-22-7.

 

Stein G M and Berg P A. Adverse effects during therapy with mistletoe extracts. In: Büssing A, editor. Mistletoe The Genus Viscum Amsterdam, Hardwood Academic Publishers; 2000. p. 195-208.

 

Stein GM and Berg PA. Mistletoe extract-induced effects on immunocompetent cells: in vitro studies. Anticancer Drugs 1997;8 Suppl 1:39-42.

 

Stein GM, Stettin A, Schultze J and Berg PA. Induction of anti-mistletoe lectin antibodies in relation to different mistletoe-extracts. Anticancer Drugs 1997;8 Suppl 1:57-59.

 

Steinborn C, Klemd A M, Sanchez-Campillo A S, Rieger S, Scheffen M, Sauer B, Garcia-Kaufer M, Urech K, Follo M, Ucker A, Kienle G S, Huber R and Grundemann C. Viscum album neutralizes tumor-induced immunosuppression in a human in vitro cell model. PLoS One, 2017;12:e0181553. DOI: 10.1371/journal.pone.0181553.

 

Stettin A, Schultze JL, Stechemesser E and Berg PA. Anti-mistletoe lectin antibodies are produced in patients during therapy with an aqueous mistletoe extract derived from Viscum album L. and neutralize lectin-induced cytotoxicity in vitro. Klin Wochenschr 1990;68:896-900.

 

Tabiasco J, Pont F, Fournie J J and Vercellone A. Mistletoe viscotoxins increase natural killer cell-mediated cytotoxicity. Eur J Biochem, 2002;269:2591-2600. DOI: 10.1046/j.1432-1033.2002.02932.x.

 

Templeton AJ, Thurlimann B, Baumann M, Mark M, Stoll S, Schwizer M, Dietrich D and Thomas Ruhstaller T. Cross-sectional study of self-reported physical activity, eating habits and use of complementary medicine in breast cancer survivors. BMC Cancer 2013;13:153. 

Thronicke A, Oei S L, Merkle A, H M and Schad F. Clinical Safety of Combined Targeted and Viscum album L. Therapy in Oncological Patients. Medicines (Basel), 2018;5:100. DOI: 10.3390/medicines5030100.

 

Thronicke A, Oei SL, Merkle A, Herbstreit C, Lemmens HP, Grah C, Kröz M, Matthes H and Schad F. Integrative cancer care in a certified Cancer Centre of a German Anthroposophic hospital. Complement Ther Med 2018;40:151-157.

 

Thronicke A, Steele M L, Grah C, Matthes B and Schad F. Clinical safety of combined therapy of immune checkpoint inhibitors and Viscum album L. therapy in patients with advanced or metastatic cancer. BMC Complement Altern Med, 2017;17:534. DOI: 10.1186/s12906-017-2045-0.

 

Tröger W, Zdrale Z and Stankovic N. Fünf-Jahres-Nachbeobachtung von Patientinnen mit Brustkrebs nach einer randomisierten Studie mit Viscum album (L.) Extrakt. Deutsche Zeitschrift für Onkologie, 2016;48:105-110. DOI: 10.1055/s-0042-113505.

 

Tröger W, Zdrale Z, Tisma N and Matijasevic M. Additional Therapy with a Mistletoe Product during Adjuvant Chemotherapy of Breast Cancer Patients Improves Quality of Life: An Open Randomized Clinical Pilot Trial. Evidence-Based Complementary and Alternative Medicine, 2014;2014:01. Sep. DOI: 10.1155/2014/430518.

 

Tröger W, Galun D, Reif M, Schumann A, Stankovic N and Milicevic M. Quality of life of patients with advanced pancreatic cancer during treatment with mistletoe: a randomized controlled trial. Dtsch Arztebl Int, 2014;111:493-502, 433 p following 502. DOI: 10.3238/arztebl.2014.0493.

 

Tröger W, Galun D, Reif M, Schumann A, Stankovic N and Milicevic M. Viscum album [L.] extract therapy in patients with locally advanced or metastatic pancreatic cancer. A randomised clinical trial on overall survival. European Journal of Cancer, 2013;49:3788-3797. DOI: 10.1016/j.ejca.2013.06.043.

 

Tröger W, Zdrale Z, Stankovic N and Matijasevic M. Five-year follow-up of patients with early stage breast cancer after a randomized study comparing additional treatment with viscum album (L.) extract to chemotherapy alone. Breast Cancer (Auckl), 2012;6:173-180. DOI: 10.4137/BCBCR.S10558.

 

Tröger W, Jezdic S, Zdrale Z, Tisma N, Hamre H J and Matijasevic M. Quality of life and neutropenia in patients with early stage breast cancer: a randomized pilot study comparing additional treatment with mistletoe extract to chemotherapy alone. Breast Cancer, 2009;3:35-45.

 

Urech K and Baumgartner S. Chemical constituents of Viscum album L. for the pharmaceutical preparation of mistletoe. In: Kurt S. Zänker, and Srini V. Kaveri, editors. (eds.), (2015) From mythology to evidence-based medicine. Translational Research in Biomedicine. Volume 4, pp 11-23.  S. Karger AG, Basel, Switzerland ISBN: 978-3-318-05444-6.

 

Urech K, C Jäggy and G Schaller (2009). Räumliche und zeitliche Dynamik der Viscotoxin- und Mistellektingehalte in der Mistel (Viscum album L.). In: Scheer R, Alban S, Becker H, Holzgrabe U, Kemper FH, Kreis W, Matthes H und Schilcher H (Hrsg.), Die Mistel in der Tumortherapie 2, S. 67-77. KVC Verlag, Essen 2009. ISBN 978-3-933351-82.

 

Urech K, Büssing A, Thalmann G, Schäfermeyer H and Heusser P. Antiproliferative effects of mistletoe (Viscum album L) extract in urinary bladder carcinoma cell lines. Anti-Cancer Research 2006;26:3049-3056.

 

Urech K, Schaller G and Jaggy C. Viscotoxins, mistletoe lectins and their isoforms in mistletoe (Viscum album L.) extracts Iscador. Arzneimittelforschung, 2006;56:428-434. DOI: 10.1055/s-0031-1296808.

 

Urech K, Scher JM, Hostanska K and Becker H. Apoptosis inducing activity of viscin, a lipophilic extract from Viscum album L. J Pharm Pharmacol 2005;57:101-109.

 

van Huyen JPD, Delignat S, Bayry J, Kazatchkine MD, Bruneva IP, Nicoletti A and Kaveri SV. Interleukin-12 is associated with the in vivo anti-tumor effect of mistletoe extracts in B16 mouse melanoma. Cancer Lett 2006;243:32-37.

 

von Hagens C, A Loewe-Mesch, JJ Kuehn, U Abel and I Gerhard (2005). Prospektive kontrollierte nicht randomisierte Machbarkeits-Studie zu einer postoperativen simultanen Mistel-/Chemotherapie bei Patientinnen mit Mammakarzinom - Ergebnisse zu Rekrutierbarkeit, Immunparametern, Lebensqualität und Verträglichkeit. In: Scheer R, Bauer H. Becker R et al. Fortschritte  in der Misteltherapie. Stand der Forschung und klinischen Anwendung. Essen, KVC Verlag, 2005. S. 567-578.

 

von Schoen-Angerer T, Wilkens J, Kienle G S, Kiene H and Vagedes J. High-Dose Viscum album Extract Treatment in the Prevention of Recurrent Bladder Cancer: A Retrospective Case Series. Perm J, 2015;19:76-83. DOI: 10.7812/TPP/15-018.

 

Weissenstein U, Kunz M, Oufir M, Wang J T, Hamburger M, Urech K, Regueiro U and Baumgartner S. Absence of herb-drug interactions of mistletoe with the tamoxifen metabolite (E/Z)-endoxifen and cytochrome P450 3A4/5 and 2D6 in vitro. BMC Complement Altern Med, 2019;19:23. DOI: 10.1186/s12906-019-2439-2.

 

Weissenstein U, Kunz M, Urech K, Regueiro U and Baumgartner S. Interaction of a standardized mistletoe (Viscum album) preparation with antitumor effects of Trastuzumab in vitro. BMC Complement Altern Med 2016;16:271. 

 

Weissenstein U, Kunz M, Urech K and Baumgartner S. Interaction of standardized mistletoe (Viscum album) extracts with chemotherapeutic drugs regarding cytostatic and cytotoxic effects in vitro. BMC Complementary and Alternative Medicine, 2014;14:01. Sep. DOI: 10.1186/1472-6882-14-6.

 

Werthmann PG, Kindermann L, Kienle GS. Chemoimmunotherapy in Advanced Renal Cell Carcinoma: A Case Report of a Long-Term Survivor Adjunctly Treated with Viscum album Extracts. Complementary Medicine Research. March 2019:1-4. DOI:10.1159/000496866 .

Werthmann PG, Kempenich R, Kienle GS. Long-term tumor-free survival in a patient with stage IV epithelial ovarian cancer undergoing high-dose chemotherapy and viscum album extract treatment: A case report. Perm J 2019;23:18-025. DOI: https://doi.org/10.7812/TPP/18-025.

Werthmann PG, Kempenich R, Lang-Avérous G, Kienle, GS. Long-term Survival of a Patient With Advanced Pancreatic Cancer Under Adjunct Treatment With Viscum album Extracts – A Case Report. World J Gastroenterol. March 2019. DOI: 10.3748/wjg.v25.i12.0000.

Werthmann PG, Kindermann L and Kienle GS. A 21-year course of Merkel cell carcinoma with adjuvant Viscum album extract treatment: A case report. Complement Ther Med 2018;38:58-60.

 

Werthmann PG, Inter P, Welsch T, Sturm AK, Grutzmann R, Debus M, Sterner MG and Kienle GS. Long-term tumor-free survival in a metastatic pancreatic carcinoma patient with FOLFIRINOX/Mitomycin, high-dose, fever inducing Viscum album extracts and subsequent R0 resection: A case report. Medicine (Baltimore) 2018;97:e13243.

 

Werthmann P G, Huber R and Kienle G S. Durable clinical remission of a skull metastasis under intralesional Viscum album extract therapy: Case report. Head Neck, 2018;40:E77-E81. DOI: 10.1002/hed.25320.

 

Werthmann PG, Saltzwedel G, Kienle GS. Minor regression and long-time survival (56 months) in a patient with malignant pleural mesothelioma under Viscum album and Helleborus niger extracts-a case report. J Thorac Dis 2017;9(12):E1064–E1070. doi:10.21037/jtd.2017.11.56.

 

Werthmann P G, Hintze A and Kienle G S. Complete remission and long-term survival of a patient with melanoma metastases treated with high-dose fever-inducing Viscum album extract: A case report. Medicine (Baltimore), 2017;96:e8731. DOI: 10.1097/MD.0000000000008731.

 

Werthmann P G, Helling D, Heusser P and Kienle G S. Tumour response following high-dose intratumoural application of Viscum album on a patient with adenoid cystic carcinoma. BMJ Case Rep, 2014;2014. DOI: 10.1136/bcr-2013-203180.

 

Werthmann P G, Strater G, Friesland H and Kienle G S. Durable response of cutaneous squamous cell carcinoma following high-dose perilesional injections of Viscum album extracts--a case report. Phytomedicine, 2013;20:324-327. DOI: 10.1016/j.phymed.2012.11.001.

 

Witt CM and Cardoso MJ. Complementary and integrative medicine for breast cancer patients - Evidence based practical recommendations. The Breast 2016;28:37-44.

 

Wode K, Schneider T, Lundberg I and Kienle G S. Mistletoe treatment in cancer-related fatigue: a case report. Cases J, 2009;2:77. DOI: 10.1186/1757-1626-2-77.

 

Wong C K, Zhang J, Ip W K and Lam C W. Intracellular signal transduction in eosinophils and its clinical significance. Immunopharmacol Immunotoxicol, 2002;24:165-186. DOI: 10.1081/IPH-120003748.

 

Xie W, Adolf J, Melzig MF. Identification of Viscum album L. miRNAs and prediction of their medicinal values. PloS one 2017;12(11):20 pp., article ID e0187776. DOI: 10.1371/journal. pone. 0187776.

 

Zänker KS, Matthes H, Bock PR, Hanisch J (2012) A Specific Mistletoe Preparation (Iscador-Qu®) in Colorectal Cancer (CRC) Patients: More than Just Supportive Care? J Cancer Sci Ther 4: 264-270. doi: 10.4172/1948-5956.1000153

 

Ziegler R and Grossarth-Maticek R. Individual Patient Data Meta-analysis of Survival and Psychosomatic Self-regulation from Published Prospective Controlled Cohort Studies for Long-term Therapy of Breast Cancer Patients with a Mistletoe Preparation (Iscador). Evid Based Complement Alternat Med, 2010;7:157-166. DOI: 10.1093/ecam/nen025.

 

Zuzak TJ, Wasmuth A, Bernitzki S, Schwermer M, Längler A. Safety of high-dose intravenous mistletoe therapy in pediatric cancer patients: A case series. Complement Ther Med. 2018 Oct;40:198-202. Epub 2018 Jan 11. DOI: 10.1016/j.ctim.2018.01.002.

Sivut päivitetty 04-05-2020

© Suomen Antroposofisen lääketieteen lääkäriyhdistys (SALLY) ry

© Mistelikuvat/Mistletoe-Images: Jürg Buess  – Institut Hiscia, Arlesheim (CH)